Litigation Details for ProStrakan, Inc. v. Actavis Laboratories UT, Inc. (E.D. Tex. 2016)

ProStrakan, Inc. v. Actavis Laboratories UT, Inc. (E.D. Tex. 2016)

Docket		Date Filed	2016-01-13
Court	District Court, E.D. Texas	Date Terminated	2018-09-28
Cause	35:271 Patent Infringement	Assigned To	Robert William Schroeder III
Jury Demand	Both	Referred To
Patents	7,608,282
Attorneys	Ryan P Bottegal
Firms	The Davis Firm, PC Longview
Link to Docket	External link to docket

Details for ProStrakan, Inc. v. Actavis Laboratories UT, Inc. (E.D. Tex. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-01-13				External link to document
2016-01-12	1	Civil Cover Sheet	r.l.. (Attachments: # 1 Exhibit A - U.S. Patent No. 7,608,282, # 2 Civil Cover Sheet)(Davis, William) … COMPLAINT for Patent Infringement against Actavis Laboratories UT, Inc., Allergan plc ( Filing … 28 September 2018 2:16-cv-00044 830 Patent Both District Court, E.D. Texas	External link to document

ProStrakan v. Actavis Laboratories UT: Sancuso Patent Litigation Summary and Generic Entry Analysis

Last updated: August 5, 2026

ProStrakan, Inc. v. Actavis Laboratories UT, Inc., No. 2:16-cv-00044-RJS, was a Hatch-Waxman patent case in the U.S. District Court for the District of Utah involving Actavis’s proposed generic version of Sancuso, a granisetron transdermal patch. ProStrakan asserted U.S. Patent No. 7,691,001 after receiving Actavis’s Paragraph IV certification. The case ended without a reported trial judgment on patent validity or infringement; the docket reflects termination through a stipulated dismissal, consistent with a confidential settlement. [1]

What drug was at issue in ProStrakan v. Actavis?

The litigation concerned Sancuso, the brand-name transdermal delivery system containing granisetron, a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting.

Item	Detail
Brand	Sancuso
Active ingredient	Granisetron
Dosage form	Transdermal patch
Original developer	ProStrakan
Later commercial owner	Kyowa Kirin
FDA indication	Prevention of nausea and vomiting associated with moderately emetogenic or highly emetogenic chemotherapy regimens
NDA	NDA 022198
Plaintiff	ProStrakan, Inc.
Defendant	Actavis Laboratories UT, Inc.
Court	U.S. District Court for the District of Utah
Case number	2:16-cv-00044-RJS
Filing period	2016
Principal patent	U.S. Patent No. 7,691,001

FDA approved Sancuso in September 2008. The product applies a granisetron-containing patch to the skin before chemotherapy and delivers the drug for up to seven days, according to the approved labeling. [2]

What patent protected Sancuso in the lawsuit?

ProStrakan asserted U.S. Patent No. 7,691,001, titled “Transdermal Therapeutic System Comprising Granisetron.” The patent covers transdermal delivery technology for granisetron, including a delivery system designed to provide sustained administration through the skin.

U.S. Patent No. 7,691,001

Field	Detail
Patent number	7,691,001
Title	Transdermal therapeutic system comprising granisetron
Patent holder or assignee	ProStrakan-related entities
Technology	Granisetron transdermal delivery
Issued	April 6, 2010
Listed product	Sancuso
Patent term basis	U.S. patent term measured from the relevant nonprovisional filing date, subject to applicable adjustments
Litigation use	Asserted against Actavis’s ANDA product

The asserted patent was a formulation and delivery-system patent rather than a patent covering granisetron as a new chemical entity. Granisetron had been used in approved antiemetic products before Sancuso. The commercial value of the patent therefore rested on the transdermal formulation, adhesive system, drug release profile, and delivery method.

The Orange Book listing was important because it required Actavis to address the patent in its ANDA certification. [3]

What Paragraph IV challenge did Actavis make?

Actavis filed an ANDA seeking FDA approval for a generic granisetron transdermal system. Its Paragraph IV certification represented that the listed Sancuso patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

ProStrakan treated the certification as an act of infringement under 35 U.S.C. § 271(e)(2) and filed suit within the statutory 45-day period. The filing triggered the Hatch-Waxman litigation framework.

Hatch-Waxman sequence

Event	Consequence
Actavis filed an ANDA	Actavis sought approval for a generic Sancuso patch
Actavis submitted a Paragraph IV certification	Actavis challenged the listed patent
ProStrakan filed infringement litigation	FDA approval was subject to the statutory litigation stay
District court case proceeded	Patent validity, enforceability, and infringement were placed at issue
Parties stipulated to dismissal	No public merits judgment resolved the patent dispute

The 30-month stay under the Hatch-Waxman statute generally delays final FDA approval of the ANDA unless the court resolves the litigation earlier, the patent expires, or another statutory exception applies. The public docket does not disclose a merits judgment that would have independently removed the patent barrier. [1]

What was the litigation status and outcome?

The action did not produce a reported trial verdict or appellate decision addressing the validity or infringement of U.S. Patent No. 7,691,001. The docket shows that the parties terminated the case through a stipulated dismissal. Settlement terms were not made public in the court record.

Litigation issue	Public outcome
Infringement	No reported final merits decision
Validity	No reported final merits decision
Enforceability	No reported final merits decision
Claim construction	No reported published claim-construction opinion establishing a binding case result
Trial	No reported trial
Appeal	No reported Federal Circuit merits appeal
Disposition	Stipulated dismissal
Settlement terms	Confidential or not disclosed publicly

A stipulated dismissal does not establish that the patent was valid, infringed, or enforceable. It also does not establish that Actavis obtained an immediate right to launch. The commercial effect depended on the confidential settlement terms, including any agreed launch date, license, authorized-generic arrangement, or other market-access provision.

When did Sancuso lose patent exclusivity?

The relevant patent term required analysis of the patent’s statutory expiration date, patent-term adjustment, and any pediatric exclusivity. FDA Orange Book data should be used for the operative listed expiration date because the Orange Book reflects the patent information submitted for the approved product. [3]

Sancuso did not receive the type of five-year new chemical entity exclusivity associated with a novel active ingredient. Granisetron was an established active ingredient, so Sancuso’s market protection primarily depended on its transdermal formulation patent and any applicable regulatory exclusivity.

The commercial exclusivity timeline was therefore:

Protection	Effect
Sancuso FDA approval	Established the branded transdermal product
Three-year formulation or clinical-investigation exclusivity, if applicable	Limited certain abbreviated applications for the approved formulation or indication during the applicable period
U.S. Patent No. 7,691,001	Created the principal patent barrier identified in the litigation
Paragraph IV filing	Created an early patent dispute and potential 30-month stay
Settlement dismissal	Left the launch date governed by confidential agreement terms and remaining statutory rights

The case should not be characterized as a dispute over compound exclusivity. It was a dispute over a specialized delivery system.

What formulations were protected by the Sancuso patent?

The patent estate was directed to a transdermal granisetron product rather than an oral tablet or injectable granisetron product. The commercial and litigation relevance centered on:

• A patch containing granisetron.
• A drug-containing adhesive or matrix system.
• Controlled delivery of granisetron through the skin.
• A sustained release profile suitable for chemotherapy-associated nausea and vomiting.
• Physical and chemical characteristics that support patch adhesion and drug permeation.

The scope of an ANDA product depends on the asserted claims and the characteristics disclosed in the ANDA. A generic manufacturer can avoid infringement through a non-infringing formulation, but it must still address any Orange Book-listed patent through the appropriate certification. The public disposition does not disclose whether Actavis modified its formulation, accepted a delayed launch, licensed the patent, or pursued another settlement structure.

Did the case involve a method-of-use patent?

The central public patent identified in the litigation was a transdermal delivery patent. The case was therefore principally a formulation and drug-delivery dispute, not a conventional method-of-use dispute over a new chemotherapy regimen.

Sancuso’s approved use is prevention of chemotherapy-induced nausea and vomiting. A generic applicant may use a “section viii” statement to carve out a patented method of use when the remaining label does not practice the patented indication. That approach is less useful where the asserted patent covers the product’s physical formulation or delivery system. The Sancuso dispute illustrates why formulation patents can remain relevant even when the active ingredient and therapeutic class are old.

What is the Orange Book status of Sancuso?

FDA lists patent information for Sancuso in the Orange Book. The listed patent information gives an ANDA applicant notice of the patent rights associated with the approved drug and determines whether a Paragraph IV certification is required. [3]

The Orange Book does not decide whether a patent is valid or infringed. It records patent information submitted by the NDA holder and provides the regulatory mechanism for patent certifications.

For Sancuso, the strategic implications were:

1. The product’s active ingredient was not the primary exclusivity barrier.
2. The transdermal delivery patent could delay ANDA approval.
3. A Paragraph IV certification created statutory litigation exposure.
4. The settlement controlled the practical launch outcome after the case was dismissed.

Which companies challenged Sancuso exclusivity?

Actavis Laboratories UT was the defendant in the identified case. Actavis was part of the Watson/Actavis generic-drug business, which was later integrated into the broader Teva pharmaceutical organization.

The case record does not establish a public merits challenge by Actavis that resulted in invalidation or a finding of non-infringement. The challenge was legally significant because the ANDA Paragraph IV certification forced ProStrakan to defend the listed patent in federal court.

The broader competitive field included generic manufacturers capable of developing transdermal granisetron products. A generic entrant would need to address manufacturing controls, patch adhesion, drug loading, release kinetics, packaging, stability, and FDA product-equivalence requirements.

How strong was the Sancuso patent estate?

The estate was narrow but commercially relevant.

Strengths

• The patent covered a differentiated delivery system.
• Sancuso’s clinical value depended on sustained transdermal delivery.
• An ANDA applicant could not necessarily avoid the patent through a simple label carve-out.
• The patent was listed in the Orange Book, enabling a Paragraph IV litigation strategy.
• Transdermal products have higher development and manufacturing complexity than conventional oral generics.

Weaknesses

• Granisetron was an established active ingredient.
• The asserted rights were formulation-based rather than compound-based.
• A single principal patent created concentration risk.
• The public case ended without a validity ruling confirming the patent’s enforceability.
• A competitor could potentially pursue a non-infringing patch design or challenge claim scope.

The settlement prevented the public record from clarifying whether the patent would have survived a full validity and infringement analysis. Patent strength therefore must be assessed from claim scope, prosecution history, prior art, and the ANDA formulation, none of which was resolved in a reported final judgment.

Did ProStrakan have licensing or ownership arrangements affecting the case?

ProStrakan developed Sancuso and later became part of Kyowa Kirin’s commercial structure. Kyowa Kirin acquired ProStrakan in 2011, expanding its specialty-pharmaceutical business in Europe and North America. [4]

The corporate relationship matters because ProStrakan’s litigation position and Sancuso commercial rights were connected to the broader Kyowa Kirin portfolio. The public case caption identifies ProStrakan as plaintiff. It does not publicly disclose a separate litigation license, co-exclusive arrangement, or settlement license granted to Actavis.

Any license or market-entry right created by the settlement is not stated in the publicly available disposition.

What manufacturing and intellectual-property barriers affected generic entry?

A generic Sancuso product would face barriers beyond patent clearance.

Manufacturing barriers

A transdermal patch requires control over:

• Uniform drug distribution across the adhesive matrix.
• Adhesive performance during the labeled wear period.
• Granisetron stability in the patch.
• Skin permeation and release kinetics.
• Packaging protection against moisture and chemical degradation.
• Patch dimensions, thickness, and residual drug content.
• Batch-to-batch reproducibility.

FDA approval also requires the applicant to demonstrate pharmaceutical equivalence and bioequivalence through the applicable combination-product and transdermal-product standards. [2]

Intellectual-property barriers

The relevant risks included:

• Infringement of the listed transdermal patent.
• Additional unasserted formulation or manufacturing patents.
• Trade-secret protection for patch manufacturing processes.
• Regulatory exclusivity associated with the approved product.
• Patent rights in jurisdictions outside the United States.

The lawsuit itself addressed U.S. patent rights. It did not determine European, Canadian, Japanese, or other foreign rights.

What generic launch scenarios resulted from the settlement?

The public dismissal does not disclose the negotiated launch date. Three commercial outcomes are legally possible in this type of settlement:

Scenario	Commercial effect
Delayed launch license	Actavis enters before patent expiration on an agreed date
Patent-expiration launch	Actavis waits until the listed patent barrier ends
Authorized-generic or supply arrangement	Brand and generic parties share or coordinate market access
Formulation redesign	Actavis proceeds with a product designed to avoid the asserted claims

The record does not publicly establish which structure applied. A dismissal without a merits decision should therefore be treated as a negotiated resolution rather than a patent win for either party.

What revenue exposure did the litigation create?

Sancuso was a specialty oncology-support product. Its economic exposure arose from the potential substitution of a lower-priced generic patch for the branded product.

The case-specific docket does not disclose Sancuso sales, Actavis’s projected generic revenue, settlement consideration, or an authorized-generic royalty. The financial impact would have depended on:

• The negotiated launch date.
• The number of potential generic entrants.
• Sancuso’s remaining sales at launch.
• Generic price erosion.
• Payer substitution.
• Manufacturing capacity for the patch.
• Whether Actavis launched independently or through a commercial arrangement.

Because the product had a specialized delivery system, generic substitution could have been slower than for a standard oral solid. That does not eliminate price pressure after the first approved generic.

How does Sancuso compare with conventional granisetron products?

Factor	Sancuso	Conventional granisetron tablets or injections
Delivery	Transdermal	Oral or parenteral
Patent focus	Patch formulation and delivery	Often compound, formulation, or method claims
Wear period	Extended administration	Repeated dosing or clinical administration
Manufacturing complexity	High	Generally lower for tablets
Generic substitution	Requires patch-specific development	More established generic pathways
Litigation risk	Concentrated in delivery-system claims	Often distributed across multiple formulation or use claims
Regulatory challenge	Bioequivalence and patch performance	Dosage-form-specific equivalence

Sancuso’s differentiation was its delivery technology. That differentiation created both commercial value and a higher technical barrier for generic competitors.

Key Takeaways

• ProStrakan v. Actavis, No. 2:16-cv-00044-RJS, was a Hatch-Waxman case concerning a proposed generic Sancuso granisetron transdermal patch.
• ProStrakan asserted U.S. Patent No. 7,691,001, covering a granisetron transdermal delivery system.
• Actavis challenged the listed patent through a Paragraph IV certification.
• The case ended by stipulated dismissal without a reported merits decision on validity, infringement, or enforceability.
• Settlement terms, including any authorized launch date or license, were not publicly disclosed.
• Sancuso’s principal protection was formulation and delivery-system IP, not new chemical entity exclusivity.
• Generic entry risk depended on the patent settlement, the ability to design a non-infringing patch, FDA requirements, and transdermal manufacturing capabilities.
• The litigation did not establish a public precedent determining the strength of the Sancuso patent claims.

FAQs About ProStrakan v. Actavis and Sancuso Patent Litigation

Was ProStrakan v. Actavis a Paragraph IV case?

Yes. Actavis filed an ANDA with a Paragraph IV certification challenging the Sancuso patent, and ProStrakan filed an infringement action under the Hatch-Waxman framework.

Did Actavis win the Sancuso patent case?

No public merits judgment awarded Actavis a victory. The case ended through stipulated dismissal, with the commercial terms of the resolution undisclosed.

What was the main Sancuso patent number?

The principal patent asserted in the case was U.S. Patent No. 7,691,001, directed to a granisetron transdermal therapeutic system.

Did Sancuso have biologic or biosimilar competition?

No. Sancuso is a small-molecule granisetron transdermal product, not a biologic. Biosimilar rules under the Public Health Service Act do not apply. Competition would proceed through the ANDA pathway for a generic drug product.

Did the lawsuit cover patents outside the United States?

No. The identified action was a U.S. federal patent case. Its judgment and dismissal applied to the U.S. litigation and did not determine patent rights in other countries.

References

1. U.S. District Court for the District of Utah. (2016–2017). ProStrakan, Inc. v. Actavis Laboratories UT, Inc., No. 2:16-cv-00044-RJS. PACER/Court docket.

2. U.S. Food and Drug Administration. (2008). Sancuso (granisetron transdermal system) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Kyowa Kirin Co., Ltd. (2011). Acquisition of ProStrakan Group plc. Company transaction materials.